Poland· PL-100478461
Prolastin
A alfa1 antitrypsin product containing alfa-1-proteinasi inhibitor humanus, registered in Poland by Grifols Deutschland GmbH. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Alfa1 antitrypsin is registered in 11 of 19 countries.
Countries holding a registration under ATC B02AB02 (alfa1 antitrypsin), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Alfa1 antitrypsin · ATC B02AB02
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
Price per daily dose
What a daily dose of alfa1 antitrypsin costs, country by country.
Normalised to the WHO defined daily dose (0.6 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Alfa1 antitrypsin · price per daily dose (0.6 g)
USD · FX 28 Sept 2026
- CH Switzerland$261.83
The record
At a glance
URPL (Poland)- Active substance
- alfa-1-Proteinasi inhibitor humanus
- Manufacturer
- Grifols Deutschland GmbH
- Country
- Poland (PL)
- ATC code
- B02AB02
- ATC class
- Alfa1 antitrypsin
- Defined daily dose
- 0.6 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991596781
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under B02AB02
Alfa1 antitrypsin, as other registers publish it.
- SwitzerlandGlassia
- CanadaGLASSIATAKEDA CANADA INC
- SwitzerlandGlassia 20 mg/ml, InfusionslösungIDEOGEN AG
- PolandProlastinGrifols Deutschland GmbH
- SwitzerlandProlastin
- NetherlandsProlastin 1000 mg, poeder en oplosmiddel voor oplossing voor infusieGrifols Deutschland GmbH
- NetherlandsProlastin 4000 mg, poeder en oplosmiddel voor oplossing voor infusieGrifols Deutschland GmbH
- IrelandProlastin 4000 mg, powder and solvent for solution for infusionGrifols Deutschland GmbH
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f8adeddd-7c33-49bf-9df2-e8f201e7a1c0 GET /v1/drugs/f8adeddd-7c33-49bf-9df2-e8f201e7a1c0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Proszek i rozpuszczalnik do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "5000 mg",
"packaging": "05909991596781 ¦ Rp ¦ 166269\n1 fiol. 5000 mg proszku ¦ 1 fiol. 200 ml rozp.",
"substance": "alfa-1-Proteinasi inhibitor humanus 5000 mg",
"common_name": "alfa-1-Proteinasi inhibitor humanus",
"pl_product_id": "100478461",
"pozwolenie_nr": "29599",
"auth_procedure": "DCP",
"authorisation_validity": "Bezterminowe"
}See everything about alfa1 antitrypsin.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.